Author: Ravi Shankar

John Chambers, PhD, and Nilanjana Sadhu, PhD, to share early insights from pioneering population-scale proteomic study of 10,000 participants in Singapore

REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2026 Human Proteome Organization (HUPO) World Congress, taking place September 27 to October 1 at the Suntec Singapore Convention & Exhibition Centre.

Led by John Chambers, PhD, Chief Scientific Officer of PRECISE and Lead PI of PRECISE-SG100K, the study represents an ambitious effort to bring deep molecular characterization to population health at unprecedented scale. By integrating proteomic data with genomic, clinical and phenotypic information from Singapore’s multi-ethnic population, PRECISE-SG100K is creating a uniquely rich resource for understanding how biological and population-level differences contribute to health and disease.

As the PRECISE-SG100K program evolved, the investigators expanded its proteomic strategy to include deep, unbiased mass spectrometry-based profiling in 10,000 participants. This complementary arm of the study combines Seer’s Proteograph® Product Suite with high-performance liquid chromatography-mass spectrometry (LC-MS), enabling researchers to interrogate the circulating proteome across a broad dynamic range and at peptide-level resolution. The approach provides an important discovery dimension to the study, allowing investigators to look beyond predefined protein targets and explore biological signals that may not have been anticipated at the outset.

In April 2026, Seer announced that the Proteograph Product Suite had been selected for this 10,000-participant component of PRECISE-SG100K. By enriching proteins across the enormous dynamic range of plasma before mass spectrometry analysis, Proteograph can increase the depth of protein coverage by approximately 7 to 10-fold compared with direct plasma analysis on leading mass spectrometry platforms. That additional depth brings into view lower-abundance proteins and potential biomarkers that can otherwise go undetected, while preserving the peptide-level information needed to investigate protein variants and other molecular differences.

For population-scale studies, depth alone is not enough. Biological signals must also be measured robustly and reproducibly across thousands of samples. The Proteograph workflow is designed to deliver consistent sample processing and high-quality proteomic data at scale, helping investigators distinguish meaningful biological variation from technical variability and increasing confidence in the signals identified across the cohort.

“As biology enters the AI era, the value of our models will ultimately depend on the richness and resolution of the biological data we can generate,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Proteins are the functional layer of biology, yet the plasma proteome spans an extraordinary dynamic range, and many potentially important disease signals are present at low abundance. Proteograph changes what mass spectrometry can see. John Chambers and the PRECISE-SG100K team have created a pioneering study that brings together population scale, diversity and deep, peptide-resolved proteomics in a way that can uncover biology that might otherwise remain hidden.”

“The combination of Proteograph enrichment and high-performance mass spectrometry has allowed us to interrogate the circulating proteome with a level of depth, consistency and reproducibility, and to bring deep biological resolution to population-scale analysis,” said John Chambers, PhD, Chief Scientific Officer of PRECISE and Lead PI of the PRECISE-SG100K study. “The proteomic data generated using this technology are already revealing proteogenomic and epidemiological signals and show strong potential to accelerate biomarker discovery and broaden the reach of precision medicine.”

Seer Breakfast Symposium

Mass Spectrometry-based Proteomics in Asian Cohort Studies: Opportunities and Challenges

Date: Monday, September 28, 2026 | Time: 7:45-8:45 a.m. SGT | Location: Room 330, Level 3

Speakers:

John Chambers, PhD, Professor, Nanyang Technological University, Singapore; Chief Scientific Officer of PRECISE and Lead PI of the PRECISE-SG100K study

Nilanjana Sadhu, PhD, Research Assistant Professor, Nanyang Technological University, Singapore; Proteomic Working Group Lead of the PRECISE-SG100K study

The PRECISE-SG100K study is a landmark effort in precision health, designed to capture genetic, molecular, clinical and phenotypic diversity across Singapore’s multi-ethnic population. As part of its broader proteomic strategy, the study incorporated the Seer Proteograph workflow combined with Thermo Scientific Orbitrap Astral™ mass spectrometry to deeply characterize the circulating proteome of 10,000 individuals. Early proteogenomic and epidemiological findings will provide a first look at the additional biological insights enabled by deep, unbiased, mass spectrometry-based proteomics at population scale.

Seer Poster Presentation

From Peaks to Power: Context-Driven Determinants of Accuracy in Large-Scale Proteomics

Date: Wednesday, September 30, 2026 | Time: 1:15 p.m. SGT | Location: Exhibit Hall | Session: PS03.002

Presenter: Lee Cantrell, Bioinformatics Scientist III, Seer

Authors: Lee Cantrell, Seth Just, Serafim Batzoglou

Population-scale proteomics creates the opportunity to make statistically powered, in-depth biological observations across large cohorts. Realizing that opportunity requires more than depth alone: quantitative fidelity and reproducibility must be maintained as studies scale. This poster examines the acquisition context required to preserve biological signal across large numbers of samples and what those requirements mean for the design of large clinical and population studies.

Together, the presentations illustrate both the scientific ambition and the technical requirements of a new generation of population proteomics studies. PRECISE-SG100K demonstrates what becomes possible when deep, peptide-resolved mass spectrometry is incorporated into a richly characterized, multi-ethnic population cohort, while From Peaks to Power examines what is required to preserve quantitative fidelity as studies reach this scale. Together, they point toward proteomic datasets with the breadth, depth and reproducibility needed to support biomarker discovery, population health research and increasingly data-intensive approaches to biology.

For more information, please visit Booth #232 at the HUPO World Congress.

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

About PRECISE-SG100K Study

The PRECISE-SG100K study is a landmark, long-term research project that has completed recruitment of over 100,000¹ participants from Singapore’s diverse, multi-ethnic population. The study has collected extensive baseline health information and biological specimens and will continue to monitor long-term health outcomes and the environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K is designed to advance precision medicine and improve health outcomes for diverse populations worldwide.

For more information, visit www.npm.sg.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s expectations about the PRECISE-SG100K collaboration, population-scale proteomics studies, and the impact of Seer’s products. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact

Patrick Schmidt
pr@seer.bio

Investor Contact

Marissa Bych
investor@seer.bio

______________________________
¹ NTD: Above we say 10,000 individuals. Confirm this 100,000 figure is distinct.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTC: AGNPF), a Canadian healthcare company, is pleased to announce the increase and closing of the second and final tranche (the “Second Tranche”) of its private placement (the “Offering”) previously announced on August 20, 2026. Gross proceeds from the Second Tranche totalled CAD $520,000, consisting of $270,000 from the sale of 675,000 units at $0.40 (the “Equity Units”) and $250,000 from the sale of unsecured convertible debenture units (the “Debenture Units”). The private placement of Equity Units and Debenture Units is collectively referred as the Offering. The first tranche of the Offering closed on September 9, 2026 totalling CAD $600,000, consisting of $285,000 from the sale of 712,500 Equity Units and $315,000 from the sale of Debenture Units. With the closing of the Second Tranche, the Offering has now closed for total proceeds of $1,120,000.

Each Equity Unit, at an issue price of CAD $0.40, consists of one Class A common share in the capital of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant entitles the holder to acquire one Common Share (a “Warrant Share“) at an exercise price of CAD $0.60 (the “Exercise Price“) per Warrant Share for a period of 36 months from the issuance date (the “Expiry Date“).

Each Debenture Unit consists of one debenture (a “Convertible Debenture”) in the principal amount of CAD $1,000 and 2,198 common share purchase warrants (a “Debenture Warrant”). The Convertible Debentures carry interest at a rate of 10% per annum from the closing date, payable semi-annually in arrears until the maturity date, which will be 24 months from the closing date of the Convertible Debentures or the conversion date of the Debentures. The outstanding principal and interest can be converted, at the option of the Convertible Debenture holder, into Common Share at a fixed price of CAD $0.455 per Common Share on or before the maturity date of the Convertible Debenture. The Company may from time to time, in its sole discretion, prepay all or a part of the principal amount and accrued interest without penalty. Each Debenture Warrant entitles the holder to acquire one Common Share (a “Debenture Warrant Share”) at an exercise price of CAD $0.55 per Debenture Warrant Share for a period of 36 months from the date of issuance.

The Company did not pay any cash finder’s fees or issue finders warrants to eligible finders in regards to the Second Tranche of the Offering.

The Company will use the proceeds of the Offering to advance its Alzheimer’s Disease program towards the opening of U.S. brain-specific neuroimaging clinic, general and administrative expenses, and for working capital purposes.

The securities issued and issuable, described in this and the previous news releases from August 20, 2026, September 10, 2026 and September 16, 2026, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration.

For more information please contact:

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

cjmoreau@greymatters-health.com
info@greymatters-health.com
www.greymatters-health.com

About Grey Matters  

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications too.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Today, Loblaw released the latest edition of its Food Inflation Report, following Statistics Canada’s release of August CPI data. While grocery inflation slowed to 2.8% year over year, falling below overall inflation for the first time in more than a year, affordability remains a significant challenge for many Canadians. 

This month’s report examines several emerging pressures that could influence food costs in the months ahead, including El Niño, commodity volatility, seafood supply constraints and the latest Canada-U.S. tariff measures. It also outlines how Loblaw is responding by helping customers identify tariff-affected products, highlighting Canadian-made and Canadian-prepared products where possible, and continuing to source competitively to deliver value. 

For more information, contact pr@loblaw.ca.

• All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well tolerated
• Strong immunogenicity demonstrated, with 100% response rate after three immunizations
• Clear antibody penetration into the cerebrospinal fluid (CSF) and signals for target engagement
• Discussions with FDA regarding future development path planned for early 2027
• AC Immune to host webcast & conference call today at 10:00am EDT / 16:00 CEST details below

Lausanne, Switzerland, September 23, 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in patients with early-stage Parkinson’s disease (PD). The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity as the basis for a Phase 3 decision. The Part 1 data reported today includes results from all 34 patients randomized into the study (25 patients receiving ACI-7104 and nine receiving placebo).

The primary endpoints for Part 1 of the VacSYn trial of ACI-7104 were safety, tolerability and immunogenicity, all of which were met. ACI-7104 was generally safe and well-tolerated and shown to be strongly immunogenic, with 100% of patients developing antibodies against the immunizing a-syn target antigen PD01 after three immunizations. Antibody reactivity against the aggregated species of a-syn was also demonstrated. Robust antibody penetration into the cerebrospinal fluid (CSF) was observed in all patients.

Part 1 of VacSYn was not designed for biomarker or clinical outcomes evaluation; however, additional exploratory analyses included monitoring the impact of ACI-7104 treatment on certain biomarkers (such as total a-syn and Neurofilament Light chain in the CSF), as well as clinical measures of disease activity. A signal was observed for total a-syn in the CSF, providing preliminary evidence consistent with target engagement. Exploratory correlation analyses identified trends suggesting an association between immunogenicity (antibody levels) and disease activity measures. While the sample size in Part 1 was limited, these observations provide a clear basis for further investigation.

The VacSYn trial of ACI-7104 in early-stage Parkinson’s disease continues in Part 1 (2-year extension) and is advancing toward the initiation of Part 2 (expansion). The final design of Part 2 is being consolidated and will be submitted to the FDA for review, with meetings expected early in 2027.

Martin Zügel, Interim CEO of AC Immune SA, commented: “The results from the complete data set at week-100 in Part 1 are encouraging, with all primary endpoints met, strong immunogenicity demonstrated, and a 100% response rate. This program is one of our strongest active immunotherapies, with ACI-7104-induced antibodies demonstrating preferential binding to aggregated a-syn species. We will now refine our approach to the next development steps in the program and discuss our plans with regulators before embarking on an expanded Phase 2 trial designed to provide evidence of clinical activity as the basis for entry into Phase 3.”

Günther Staffler, Executive Vice President, Development at AC Immune SA, commented: “We are pleased to have observed strong and boostable immune responses, with significant antibody penetration into the CSF and signals for target engagement. Together with the favorable safety profile through week-100, and exploratory correlations between antibody titers and disease activity measures, we are confident that these results provide a strong foundation for the continued development of ACI-7104 into Part 2.”

Conference call details:
Participants may call the following numbers, 10 – 15 minutes before conference start

Switzerland / Europe:    +41 (0) 58 310 50 00

United Kingdom:           +44 (0) 203 059 58 63

United States:               +1 (1) 631 570 56 13

HD Web Phone™:        Click Here

Other international numbers available HERE

Webcast link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=lUHjSJWK

A live and archived webcast will also be accessible in the Investors section of the Company’s website at https://www.acimmune.com/.

Ends

For further information, please contact:

SVP, Investor Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com
International Media Optimum Strategic Communications Nick Bastin, Joshua Evans, Aoife Minihan, Ben Cowe Phone: +44 (0) 20 4566 8543 Email: acimmune@optimumcomms.com

About VacSYn

VacSYn (ClinicalTrials.gov: NCT06015841) is an adaptive, randomized, double-blind, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two parts. Part 1 includes 34 patients randomized 3:1 to receive ACI-7104 or placebo, respectively. The results reported today include data from all participants 100 weeks since initiation of treatment. The study is being conducted in two parts with the aim for Part 1 being to show safety, tolerability and immunogenicity while Part 2 is designed to provide evidence of clinical activity and support a Phase 3 decision.

About ACI-7104

ACI-7104.056 is an optimized formulation of its clinically validated anti-a-syn predecessor active immunotherapy that generated a target-specific antibody response against pathological oligomeric a-syn to inhibit spreading and downstream neurodegeneration in early Parkinson’s disease. The accumulation of alpha-synuclein protein aggregates has been shown to cause inflammatory stress in cells and contribute to the degeneration of neurons in the brain. It has been known to play a key role in the development of neurodegenerative diseases such as Parkinson’s Disease.

About AC Immune SA 

AC Immune (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company developing a pipeline of products, including both active immunotherapies and small molecules, targeting key misfolded proteins and pathways for the treatment of multiple neurodegenerative diseases. The company has a growing focus on its wholly owned proprietary clinical-stage programs, including: ACI-7104, an active immunotherapy targeting α-synuclein (α-syn) in Parkinson’s disease; and ACI-19764, a small molecule inhibitor of the NLRP3 inflammasome. In addition, an early-stage small molecule development program targeting intracellular a-syn is advancing towards the clinic.

ACIU has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding and >$4.5 billion in potential milestone payments, plus royalties from sales. ACIU’s pharma-partnered programs, all in Alzheimer’s disease, include: a collaboration on ACI-24, an active immunotherapy targeting Abeta; a collaboration on ACI-35 targeting phospho-Tau; and a collaboration developing brain-penetrant small molecule drugs targeting intracellular pathologic Tau.

All trademarks used or mentioned in this release are protected by law. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

• FINAL__ACIU ACI-7104 Part 1 week 100 VacSYn Phase 2 results PR

• Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12
• Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-1402 in CLE
• IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies
• All other clinical development timelines remain on track

BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant’s proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).

The study did not achieve statistical significance on its primary endpoint of percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at Week 12. Numerical trends favoring IMVT-1402 over placebo were observed across multiple endpoints, and patients who achieved deeper IgG reductions from baseline were more likely to achieve improved clinical responses. However, due to the competitive landscape and the clinical results observed, Immunovant plans to stop development in CLE.

“On behalf of everyone at Immunovant, I want to thank the patients living with CLE who volunteered for this study and the investigators and clinical site teams who conducted it with such care. Their contributions advance our understanding of FcRn inhibition in autoimmune disease and will inform our work going forward,” said Eric Venker, M.D., Pharm.D., Chief Executive Officer of Immunovant.

Immunovant remains focused on rapidly advancing the clinical development of IMVT-1402 across multiple autoimmune diseases with significant unmet need, including Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjogren’s disease.

About the Proof-of-Concept Study of IMVT-1402 in CLE
The proof-of-concept clinical study (NCT06980805) of IMVT-1402 (imeroprubart) in CLE is a randomized, double-blind, placebo-controlled, global trial that assessed the safety and efficacy of IMVT-1402 in adult patients with CLE. The study enrolled 57 patients. In Period 1, patients were randomized to IMVT-1402 vs. placebo for a 12-week treatment period. The primary endpoint was the percent change from Period 1 baseline in CLASI-A score at Week 12.

About Immunovant
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant (Nasdaq: ROIV). As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

About Roivant
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA^™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com
Media
Stephanie Lee
stephanie.lee@roivant.com

PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz^®.

“The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team’s continued execution on technically demanding formulations, and the launch adds further momentum to our commercial portfolio.  Our U.S. focused generics business continues to produce outstanding results, and we remain on track to launch at least 15 new generics this year,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.

U.S. annual sales for Everolimus Tablet for Oral Suspension totaled approximately $123 million, based on July 2026 moving annual total (MAT) IQVIA data.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the Company’s strategy; its plans with respect to the commercialization and potential sales of the Company’s products, including the launch of Everolimus; its efforts to bring limited-competition products to market and ensure that is high-quality products are readily accessible to its customers and patients in need; expansion plans for the Company’s Rare Disease, Generics and Brands businesses; and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” the negatives thereof, or other words of similar meaning, derivations of such words and the use of future dates.

Uncertainties and risks may cause the Company’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to: the ability of the Company’s approved products to achieve commercialization at levels of market acceptance that will allow the Company to maintain profitability; delays and disruptions in the production of the Company’s approved products; delays or failure to obtain or maintain approvals by the FDA of the Company’s products; changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration and other regulatory agencies; risks that the Company may face with respect to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of the Company’s products from both domestic and overseas sources due to supply chain disruptions or for any other reason; the limited number of suppliers for active pharmaceuticals ingredients for our products; the ability of the Company’s manufacturing partners to meet its product demands and timelines; the level of competition the Company faces and the legal, regulatory and/or legislative strategies employed by its competitors to prevent or delay competition from generic alternatives to branded products; the impact of legislative or regulatory reform on the pricing for pharmaceutical products; the Company’s ability, and that of its suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries; legal proceedings and product liability claims relating to our products and our business; and general business and economic conditions, such as inflationary pressures and geopolitical conditions.

More detailed information on these and additional factors that could affect the Company’s actual results are described in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, and other periodic reports, as well as other filings with the SEC. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company’s current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: Irina.koffler@anipharmaceuticals.com

Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com

Source: ANI Pharmaceuticals, Inc.

• New coolant distribution unit, the WCDU, is designed for a wide-range of configurations and optimized to meet the need for high-capacity technical corridor-based cooling architectures
• Seamless integration with air cooling configurations and multiple installation options give operators greater flexibility
• Single WCDU provides cooling capacity up to 3.5MW, with an accessible design for simplified high-density deployment in space-constrained environments
• Supports approach temperature differences as low as 2 °C to improve PUE and reduce OpEx for the entire cooling system

RUEIL-MALMAISON, France, Sept. 23, 2026 (GLOBE NEWSWIRE) — Schneider Electric, a global energy technology leader, today launched its WCDU, a coolant distribution unit suitable for a wide range of configurations and is designed for seamless integration with fan wall air-cooling systems to support hybrid air and liquid cooling architectures in high-density AI data centers. Designed for greater deployment flexibility, the unit allows operators to adjust the balance of liquid and air cooling without fully redesigning the data hall. This approach allows for versatility as workloads are finalized to avoid overbuilt infrastructure and stranded capacity.

The new WCDU reflects the evolution of liquid cooling and matches changing infrastructure deployments for the AI era. Large data centers operators are increasingly deploying CDUs outside of the white space in the technical corridor for easier service and maintenance. The WCDU is optimized for the technical corridor and equipped with top entry connections to reduce installation complexity and keep the white space clear, which simplifies installation and service access.

“As the only CDU that brings together both liquid and air cooling within a single solution, we’re delivering a level of flexibility the market hasn’t seen before,” said Andrew Bradner, Senior Vice President of the Cooling Business at Schneider Electric. “This approach allows operators to deploy more efficiently, support a wider range of liquid cooling infrastructure configurations, and significantly reduce time to deployment.”

The new addition complements, expands and strengthens the Motivair by Schneider Electric line of liquid cooling solutions, which includes a range of CDUs to match a broad range of row-based, corridor-based and other deployment architectures.

Additional Key Benefits of the WCDU

The WCDU’s all-in-one design, which incorporates Integrated pumps, heat exchangers and other critical CDU components into a single steel frame, simplifies deployment and provides multiple installation options through a scalable, multi-modal architecture. In addition to integrating with fan walls, the WCDU can be used as a standalone unit. As a result, operators currently using fan walls for their cooling infrastructure gain an easier path to retrofitting their facilities. The unit also maintains zero lateral clearance, enabling optimized density in existing and new data hall layouts. The WCDU also supports:

• Increased Density: The WCDU offers the single largest cooling capacity in the Motivair by Schneider Electric CDU line. A single WCDU is able to achieve capacity up to 3.5 MW at 1.5 liters per minute per kW, and 2.5 MW at 2.0 liters per minute per kW. Up to 20 WCDU units can operate together in group mode as a coordinated system, offering the scale needed to support today’s 30-40MW data halls.
• Improved efficiency: Supports warmer facility water system temperatures and approach temperature as low as 2°C. These operating conditions help improve PUE and improve the energy efficiency of the entire cooling infrastructure, which contributes to lower overall operating costs. The system incorporates hot swappable pumps, PICVs, and 25 micron filters, as well as a 15 inch touchscreen HMI to support resiliency.
• Supports resiliency: As an additional resilience option, for deployments up to 2.5 MW, the WCDU can be specified with N+1 redundancy, providing pump and valve backup to help maintain cooling availability during maintenance or an unexpected component outage.

With the addition of the WCDU, Schneider Electric’s end-to-end liquid cooling portfolio now offers CDUs ranging from 105kW to 3.5MW, meeting current and future performance requirements.

The WCDU will begin shipping in select regions in October 2026 and will be available for pre-order in the U.S. beginning in early 2027. For more information, visit Schneider Electric’s website.

Press contact: mediarelations@se.com

Related resource:

• Reference design that evaluates the deployment of the WCDU in an AI-ready data center environment using CFD (Computational Fluid Dynamics) analysis.

About Schneider Electric

Schneider Electric is a global energy technology leader, driving efficiency and sustainability by electrifying, automating, and digitalizing industries, businesses, and homes. Its technologies enable buildings, data centers, factories, infrastructure, and grids to operate as open, interconnected ecosystems, enhancing performance, resilience, and sustainability. The portfolio includes intelligent devices, software-defined architectures, AI-powered systems, digital services, and expert advisory. With 160,000 employees and 1 million partners in over 100 countries, Schneider Electric is consistently ranked among the world’s most sustainable companies. 

www.se.com

Learn more about Advancing Energy Tech on Schneider Electric Insights.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/756f3c46-0cfb-4ca9-a679-77e384ebffcc

Approximately $507,000 invested to reactivate Panuco operations; additional capital deployment planned as NEXT10 targets increased gold production through mid-2027

GREEN VALLEY, Ariz., Sept. 23, 2026 (GLOBE NEWSWIRE) — NEXT10, Inc. (OTC: NXTN) (“NEXT10” or the “Company”), through Torreon Group, Inc., today announced that it activated its first mining operation in Mexico and commenced gold production at the Panuco gold mining operation effective August 1, 2026.

Earlier this year, NEXT10 invested approximately $507,000 in equipment, infrastructure and operating improvements to reactivate the Panuco operation. The Company currently expects to deploy approximately an additional $240,000 in the coming weeks as part of the next phase of production expansion.

Gold production began August 1 and is currently operating at approximately 20 ounces per month. As additional equipment, infrastructure and processing capacity are installed, management is targeting production of approximately 320 ounces of gold per month by mid-2027.

The operation is currently generating revenue, which the Company expects to begin reflecting in its reported financial results over the coming quarters.

The milestone represents an important transition for NEXT10 as the Company moves from acquiring and developing hard-asset opportunities into the activation, operation and expansion of revenue-producing assets.

“This is where strategy becomes an operating business,” said John B. Hayden, Chairman and Chief Executive Officer of NEXT10, Inc. “Earlier this year, we committed approximately $507,000 to put this operation back to work. Gold production began August 1, the operation is now generating revenue, and we are continuing to invest behind the asset as we expand its productive capacity.”

Hayden continued, “After more than four decades in business, I have learned that sustainable growth is built in stages. You deploy capital, establish operations, prove the process and then invest further where the results support it. We are currently producing approximately 20 ounces of gold per month. With the equipment, infrastructure and additional capital we plan to deploy, our objective is to build toward approximately 320 ounces per month by mid-2027. That disciplined approach to capital deployment is one we intend to apply across the NEXT10 portfolio.”

The Company expects to continue investing in processing equipment, infrastructure and operating capacity over the coming months. These investments are intended to increase throughput, improve recovery capabilities and support the planned production ramp.

The approximately 320-ounce-per-month production objective is a management target and should not be interpreted as a guarantee of future production. Actual results may vary materially depending on equipment installation and commissioning, mine conditions, processing performance, recovery rates, available capital, commodity prices, operating costs and other operational and market factors.

NEXT10 intends to provide additional operating and financial updates as material milestones are achieved.

About NEXT10, Inc.

NEXT10, Inc. (OTC: NXTN), through Torreon Group, Inc. and its affiliated businesses, is focused on acquiring, developing and operating businesses and assets with an emphasis on opportunities backed by real estate and other hard assets.

The Company’s strategy is to identify assets where additional capitalization, operating discipline and active management may improve operations, generate cash flow and create long-term enterprise value.

For additional information, visit www.torreongroupinc.com.

Mining and Technical Information

Unless expressly stated otherwise, information concerning production potential, anticipated grades, recoveries, throughput and future mining or processing activities is based on information provided by the Company, project operators and management estimates.

Commodity Prices and Capital Requirements

Future financial performance may be affected materially by changes in gold, copper and other commodity prices. The Company does not control commodity prices and makes no representation that any assumed or projected commodity price will be realized.

The Company’s planned production expansion also depends, in part, on the availability and successful deployment of additional capital. There can be no assurance that required capital will be available when needed or on terms acceptable to the Company.

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other matters, planned investments in mining equipment and infrastructure; anticipated increases in gold production; the Company’s target of approximately 320 ounces of gold production per month by mid-2027; future revenue and financial results; and NEXT10’s broader operating and growth strategy.

Forward-looking statements are based on management’s current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

These risks include, among others, equipment availability and commissioning, mining and processing performance, recovery rates, geological and operating conditions, commodity prices, operating costs, capital requirements, financing availability, regulatory matters and general economic and market conditions.

There can be no assurance that planned investments will result in the targeted production levels, revenue or profitability. Past performance, historical results and management estimates are not guarantees of future results.

Forward-looking statements speak only as of the date of this release. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement.

Contact

John B. Hayden
CHAIRMAN/CEO
TORREON GROUP INC/NEXT10
ir@torreongroupinc.com

All amounts in this release are in U.S. dollars unless otherwise indicated.

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — Highlander Silver Corp. (TSX, NYSE American: HSLV) (“Highlander Silver” or the “Company”) is pleased to announce that it has executed a mandate letter with Natixis Corporate & Investment Banking (“Natixis CIB”) to lead a fully underwritten 7-year senior secured structured project finance facility of $330 million (the “Facility”) to fund the development and construction of the Corani Silver Project in Peru. The financing will be supported by a cost overrun facility of up to $100 million to be established prior to first draw and provided by the Company; final facility amounts will be subject to due diligence. As of June 30, the Company reported a cash balance of approximately $100 million and no debt.

Natixis CIB brings deep expertise in structuring project financing for large-scale mining developments, reinforcing the Corani Silver Project as a globally recognized, bankable asset. The execution of this mandate letter represents a major milestone in advancing towards a fully funded construction package.

Daniel Earle, President & CEO of Highlander Silver, commented:

“Highlander Silver is delighted to partner with Natixis CIB, which is widely regarded as one of the world’s leading project finance institutions, with a distinguished track record of financing successful development projects. The Facility represents a strong endorsement of the Corani Silver Project, providing high-quality capital that follows a rigorous multidisciplinary due diligence process across key technical, financial, environmental and social aspects of the project that set it apart from recent peer financings in the high-yield and convertible debt markets. Importantly, Highlander Silver has retained 100% of the offtake rights to the project to preserve optionality and maximize future value amidst an intensifying global competition for clean concentrates.”

The Facility is subject to completion of definitive documentation, which will include customary project finance terms, fees and conditions, credit approvals, and the completion of ongoing detailed technical, financial, environmental and social due diligence. Closing is expected in the first quarter of 2027.

About Natixis Corporate & Investment Banking

Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide. As part of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor’s: A+, Moody’s: A1, Fitch: A+, R&I: A+).

On behalf of Highlander Silver

“Daniel Earle”
President and CEO

Information contact

Arun Lamba, Vice President Corporate Development
alamba@highlandersilver.com

About Highlander Silver

Highlander Silver is a high-quality silver-growth company developing a portfolio of advanced-stage assets in Peru which includes the bonanza-grade San Luis gold-silver project, which ranks among the 10 highest-grade projects globally in both gold and silver categories, and the Corani silver project, the largest silver deposit in development globally.¹ The Company also operates the Mercedes gold-silver mine in Mexico. Highlander Silver’s major shareholders include the Augusta Group, Lundin family, and Eric Sprott.

Forward-looking statements

Certain information contained in this news release constitutes “forward-looking information” under Canadian securities legislation. This includes, but is not limited to: statements regarding the Facility, including its anticipated amount, tenor, interest rate, spread and other terms; the timing and ability of the Company to complete and draw under the Facility; the completion of definitive documentation, ongoing due diligence; the establishment and amount of a cost overrun facility; the anticipated timing of closing; the use of proceeds of the Facility to fund development of the Corani Silver Project. Such forward looking information or statements can be identified by the use of words such as “anticipates”, “expects”, “intends”, “believes”, “plans”, “may”, “subject to” or “underway” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “will” be taken, occur, or be achieved. Forward-looking information is based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, including: that due diligence and definitive documentation will be completed on terms consistent with the mandate letter; the applicable conditions precedent will be satisfied; the cost overrun facility will be available on acceptable terms; and there will be no material adverse change affecting the Company, the Corani Silver Project or the financing markets. Forward-looking information involves known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company and/or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking information. Such factors include, among others: general business, economic, competitive, political and social uncertainties; the actual results of current exploration activities; changes in project parameters as plans continue to be refined; future prices of precious and base metals; accident, labour disputes and other risks of the mining industry; delays in obtaining governmental or stock exchange approvals or financing; and risks related to the Facility, including that definitive documentation may not be completed on the terms contemplated or at all, ongoing due diligence may not be completed to the satisfaction of Natixis CIB, conditions precedent may not be satisfied, the cost overrun facility may not be established on acceptable terms or at all, closing or drawdowns under the Facility may be delayed or may not occur, interest rates may change, or project costs may increase, or the development of the Corani Silver Project may be delayed, cost more than anticipated or be adversely affected by technical, environmental, social, permitting, construction or other development risks. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that could cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein is made as of the date of this news release. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws. Accordingly, the reader is cautioned not to place undue reliance on forward-looking information.

^{1 S&P Global rankings including the Corani silver project and San Luis gold-silver project.}

HANGZHOU, China, Sept. 23, 2026 (GLOBE NEWSWIRE) — On September 22, CaoCao Inc. (“CaoCao” or the “Company”) announced a partnership with Qwen AI Glasses at the 2026 Apsara Conference. The two parties will jointly launch an AI ride-hailing service featuring hands-free, near-eye interaction. Following integrations with Doubao Mobile Assistant, HONOR YOYO and OPPO Breeno, CaoCao is further expanding its on-device AI hardware service ecosystem, extending its ride-hailing services to smart wearable devices.

The partnership creates a complete closed loop of “device sensing + model understanding + service fulfillment”: Qwen AI Glasses sense user needs and provide trip-related prompts, the Qwen foundation model breaks down and matches those needs, and CaoCao ultimately fulfills the mobility service in the physical world.

To use the ride-hailing service, users simply put on Qwen AI Glasses and state their destination. The system can then automatically identify the pickup and drop-off locations, select the best route and get an estimate. During the trip, users can modify their destination or confirm the vehicle type for pickup at any time using voice commands. If they need to communicate with the driver, they can also initiate voice contact directly through the glasses. Key information, including the pickup vehicle and trip progress, is displayed as visual cards in the user’s field of view, keeping users informed throughout the journey.

On the technical side, the partnership adopts a two-layer architecture that combines MCP and Skill. CaoCao’s MCP Server is registered as a plugin on the Qwen Open Platform, exposing its full suite of mobility service capabilities to the platform. Interaction logic is handled by a Qwen AI Glasses Skill, which can flexibly orchestrate service calls, voice output and on-screen presentation for different use cases. This two-layer design allows CaoCao to focus on updating its mobility service capabilities, while the Qwen Open Platform can independently optimize the interaction experience. Each side can iterate independently, delivering a smoother user experience.

Contact:
Jing Liu   
Jing.Liu3@caocaoglobal.com